Ancrod and Fibrin Formation
Autor: | Shuo Liu, Victor J. Marder, David E. Levy, Annlia Paganini-Hill, Mark Fisher, Shur-Jen Wang, Fan Yang |
---|---|
Rok vydání: | 2011 |
Předmět: |
Ancrod
medicine.medical_treatment Venom Pharmacology Fibrinogen Article Fibrin Fibrinolysis medicine Humans Malayan pit viper Cells Cultured Advanced and Specialized Nursing biology business.industry Stroke Clinical trial Culture Media Conditioned Ischemic stroke Immunology biology.protein Endothelium Vascular Neurology (clinical) Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Stroke. 42:3277-3280 |
ISSN: | 1524-4628 0039-2499 |
Popis: | Background and Purpose— Ancrod, derived from Malayan pit viper venom, has been tested as ischemic stroke treatment in clinical trials with inconsistent results. We studied the actions of ancrod on fibrinolysis pathways in patient plasma samples and endothelial cell culture systems. Methods— We analyzed fibrinogen levels during the first 6 hours of ancrod infusion in patients entered in the Stroke Treatment with Ancrod Trial. For the in vitro study, human brain microvascular endothelial cells incubated with plasminogen or with human brain microvascular endothelial cell-conditioned medium were co-incubated with ancrod and fibrinogen under normal or oxygen-glucose deprivation conditions over 6 hours. Results— Fibrinogen levels decreased both in vivo and in vitro. Ancrod generated fibrinopeptide A, caused visible clot formation, and reduced levels of tissue-type plasminogen activator antigen in the human brain microvascular endothelial cell system and in a cell-free system with conditioned media. Conclusions— The in vitro results indicate that ancrod causes local fibrin formation and secondary depletion of tissue-type plasminogen activator by binding to fibrin clot. Ancrod-induced fibrin formation could result in cerebral microvascular occlusion and may explain the suboptimal clinical effects of ancrod in human stroke trials. |
Databáze: | OpenAIRE |
Externí odkaz: |